Key clinical point: Telomerase inhibitors may help some patients with myelodysplastic syndrome achieve durable transfusion dependence.
Major finding: Of 38 patients, 16 remained transfusion independent for a median of 86 weeks.
Study details: A single-arm, open label study of imetelstat in 38 patients with low or intermediate-1 risk MDS.
Disclosures: The study is supported by Geron Corp. Dr. Fenaux reported relationships with Janssen, Celgene, Astex, and Agios. Dr. Hagenbeek reported having no relevant disclosures.
Fenaux P et al. EHA Congress, Abstract S837.